关于美国《罕见病药物法案》(OrphanDrugAct),表述正确的是: A. 1983年通过 B. 罕见性疾病是指患者人数不超过200,000人的疾病 C. 该法案规定
in Selling Orphan Drugs Disincentives and Obstacles for Orphan Drug Development US Orphan Drug Act of 1983 Establishing Prevalence or Incidence of a Disease Establishing Differences Among Medicines Rating the Effects of the Orphan Drug Act in the USA Europe Rest of the World What Has Been Learned?
The orphan drug act of 1983:a case study of issue framing and the failure to effect policy change from 1990 - 1994[D]. Carolina:The University of North Carolina at Chapel Hill,2009:1.Redington L. The Orphan Drug Act of 1983:a case study of issue framing and the failure to effect ...
1983年1月4日美国国会通过的美国《罕见病药物法》(Orphan Drug Act)是根据《联邦食品药品和化妆品法》(Frederal Food…www.healthoo.com|基于30个网页 2. 罕见病药品法 通过《罕见病药品法》(ORPHAN DRUG ACT),使FDA能鼓励治疗罕见病(rare diseases)需要的药品的研究和上市。 198…www.fdc-intl.com|基于23个...
aSorry I was traveling 正在翻译,请等待...[translate] aFor these reasons, in 1983, Congress passed the Orphan Drug Act, 为这些原因, 1983年国会通过了孤儿药物行动,[translate]
关于美国《罕见病药物法案》 OrphanDrugAct 表述正确的是 A、 1983年通过 B、 罕见性疾病是指患者人数不超过200,000人的疾病 C、 该法案规定制药公司可以获得罕见病药物新药批准后7年的市场独占权 D、 该法案规定开发罕见病药物的临床试验费用可享受减税政策 该题目是多项选择题,请记得选择多个答案!正确...
Since its passage in 1983, the US Orphan Drug Act has led to the approval of more than 350 drugs for around 200 rare diseases, mostly thanks to small biotech startups looking for a unique niche in the marketplace. Yet with the demise of ... Dolgin,Elie - 《Nature Medicine》 被引量...
Define Orphan Drug Act. Orphan Drug Act synonyms, Orphan Drug Act pronunciation, Orphan Drug Act translation, English dictionary definition of Orphan Drug Act. n. a drug that remains undeveloped or is neglected because of limited potential for commercial
The Orphan Drug Act is not about children without parents. 这个孤儿药法案与失去父母的孩子无关。 The term "orphan drugs" refers to medical products that would not be adopted by major pharmaceutical companies 孤儿药品这个术语是指非主要制药公司生产的药品。 because they serve only a very small por...
Joppi R, Bertele V, Garattini S (2009): Orphan drug development is not taking off. Br J Clin Pharmacol 67: 494–502. ArticlePubMedCASGoogle Scholar Kantarjian HM, Talpaz M, Giles F, O‘Brien S, Cortes J (2006): New insights into the pathophysiology of chronic myeloid leukemia and ...